These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 34575843)
1. Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges. Hefazi M; Bolivar-Wagers S; Blazar BR Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575843 [TBL] [Abstract][Full Text] [Related]
2. Advances in the treatment of graft-versus-host disease with immunomodulatory cells. Yu Q; Wang H; Zhang L; Wei W Int Immunopharmacol; 2021 Mar; 92():107349. PubMed ID: 33486323 [TBL] [Abstract][Full Text] [Related]
3. Regulatory T Cells in GVHD Therapy. Guo WW; Su XH; Wang MY; Han MZ; Feng XM; Jiang EL Front Immunol; 2021; 12():697854. PubMed ID: 34220860 [TBL] [Abstract][Full Text] [Related]
4. Regulatory T cells in allogeneic hematopoietic stem cell transplantation: From the lab to the clinic. Gu G; Yang JZ; Zhang JQ; Sun LX Cell Immunol; 2019 Dec; 346():103991. PubMed ID: 31607390 [TBL] [Abstract][Full Text] [Related]
5. Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease. Hippen KL; Hefazi M; Larson JH; Blazar BR Front Immunol; 2022; 13():926550. PubMed ID: 35967386 [TBL] [Abstract][Full Text] [Related]
6. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. Mohamed FA; Thangavelu G; Rhee SY; Sage PT; O'Connor RS; Rathmell JC; Blazar BR Front Immunol; 2021; 12():757836. PubMed ID: 34712243 [TBL] [Abstract][Full Text] [Related]
7. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT. Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB Front Immunol; 2018; 9():3104. PubMed ID: 30733722 [TBL] [Abstract][Full Text] [Related]
8. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease. Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B Front Immunol; 2020; 11():181. PubMed ID: 32117306 [TBL] [Abstract][Full Text] [Related]
9. Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives. Ikegawa S; Matsuoka KI Front Immunol; 2021; 12():713358. PubMed ID: 34526990 [TBL] [Abstract][Full Text] [Related]
11. The role of regulatory T cells in graft-versus-host disease management. Whangbo JS; Antin JH; Koreth J Expert Rev Hematol; 2020 Feb; 13(2):141-154. PubMed ID: 31874061 [No Abstract] [Full Text] [Related]
12. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation]. Yang K; Fan ZP; Liu QF; Zhang Y Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584 [TBL] [Abstract][Full Text] [Related]
13. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation. Bertaina A; Roncarolo MG Front Immunol; 2019; 10():1342. PubMed ID: 31354695 [TBL] [Abstract][Full Text] [Related]
14. Granzyme A Is Required for Regulatory T-Cell Mediated Prevention of Gastrointestinal Graft-versus-Host Disease. Velaga S; Ukena SN; Dringenberg U; Alter C; Pardo J; Kershaw O; Franzke A PLoS One; 2015; 10(4):e0124927. PubMed ID: 25928296 [TBL] [Abstract][Full Text] [Related]
15. Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation. Meguri Y; Asano T; Yoshioka T; Iwamoto M; Ikegawa S; Sugiura H; Kishi Y; Nakamura M; Sando Y; Kondo T; Sumii Y; Maeda Y; Matsuoka KI Front Immunol; 2022; 13():891925. PubMed ID: 35983059 [TBL] [Abstract][Full Text] [Related]
16. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia. Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P Front Immunol; 2021; 12():605766. PubMed ID: 34025637 [TBL] [Abstract][Full Text] [Related]
18. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation. Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835 [TBL] [Abstract][Full Text] [Related]
19. The impact of regulatory T cells on the graft-versus-leukemia effect. Pacini CP; Soares MVD; Lacerda JF Front Immunol; 2024; 15():1339318. PubMed ID: 38711496 [TBL] [Abstract][Full Text] [Related]
20. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation. Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]